cyrilzakka/clinical-trials huggingface dataset:
Washed Microbiota Transplantation for Tourette's Syndrome

This study aimed to evaluate the efficacy of washed microbiota transplantation in the treatment of Tourette's syndrome (TS).

Emerging scientific data support the significant role of microbiota in the modulation of the central nervous system. The reconstitution of gut microbiota might be a potential option to treat Tourette's syndrome (TS). FMT has been reported to be a highly effective therapy to restore the gut microbiota dysbiosis by transferring gut microbiota from healthy donors to patients. The newly improved methodology of FMT based on the automatic washing process and the related delivering consideration was named as washed microbiota transplantation (WMT) by the FMT-standardization study group. FMT has shown treatment potential in several gut-brain axis-related disorders, such as amyotrophic lateral sclerosis and Parkinson's disease, promoting us to investigate its treatment potential for Tourette's syndrome. In this study, investigators aimed to evaluate the efficacy of WMT for Tourette's syndrome and its comorbidities using specialized questionnaires for Tourette's syndrome and investigate the underlying mechanism.

Eligibility Criteria:
Inclusion Criteria:

1. Patients were aged 6 to 17 years (inclusive);
2. Met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for TS;
3. Had a Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS) of at least 20 at screening and baseline.
4. Underwent WMT.

Exclusion Criteria:

1. Complicated with certain brain disease, including tumor,injury,cerebrovascular disease;
2. Complicated with other severe disease, including cancers, organ failure, heart diseases;
3. Stereotypy associated with autism spectrum disorder;
4. With a confirmed diagnosis of psychiatric diseases, such as bipolar disorders; schizophrenia and major depressive disorders;
5. Clinically significant obsessive-compulsive disorder at baseline considered to be the primary cause of impairment at baseline;
6. Medications use affecting gut microbiota such as antibiotics and probiotics three months before WMT.
7. Other neurologic disorders other than TS that could influence the evaluation of tics.
Continuous Postoperative Pulse Oximetry in Patients Presenting for Total Hip and Total Knee Replacement

The purpose of this study is to evaluate the incidence of low levels of oxygen as determined by standard pulse oximetry monitor in patients who have had total hip or knee replacement/revision.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing knee replacement or hip replacement/revision

Exclusion Criteria:

* Patients requiring mechanical ventilation after surgery
* Patients with hemoglobinopathy that cause inaccurate pulse oximetry
52 Week Trial of Liraglutide in Type 1 Diabetes

To our knowledge, no trial has specifically studied the effect of liraglutide combined with a basal/bolus insulin regimen in type 1 diabetes in a cross-over, double-blind, unicentric model. Moreover, the potential impact of a glucagon-like peptide-1 agonist on measures of abdominal fat (assessed by CT scan), insulin sensitivity (assessed by the gold standard euglycemic-hyperinsulinemic clamp) and satiety sensations have not been evaluated in this population.

Hypothesis Overweight participants with type 1 diabetes on liraglutide/insulin treatment will present improved glucose control with decreased HbA1c, decreased fasting and mean weekly glucose concentrations and glycemic excursions as well as increased insulin sensitivity compared to participants on placebo/insulin treatment. Participants with liraglutide/insulin treatment will also present improved endothelial function, lower body weight, central adipose tissue assessed by CT scan and higher satiety sensations assessed by visual analogue scales.

Participants will be submitted to this double-blind cross-over protocol of 52-week use of liraglutide/placebo.

Eligibility Criteria:
Inclusion Criteria:

* type 1 diabetes non smoker BMI superior or equal to 25 diabetes duration superior or equal to 5 years

Exclusion Criteria:

* diabetic complication HbA1c superior or equal to 8.5% cancer acute or chronic pancreatitis
Motivational Strategies in Batterer Intervention Programs for Offenders With Alcohol/Drug Abuse Problems (IMP-ADAPs)

Alcohol and/or drug abuse problems (ADAPs) have been consistently identified in the scientific literature as a risk factor of intimate partner violence against women (IPVAW). Around 50% of IPVAW offenders referred to batterer intervention programs (BIPs) have ADAPs. ADAPs are also one of the main predictors of BIPs dropout. In Spain, the majority of BIPs do not fit the intervention to specific needs or characteristics of IPVAW offenders, such as those with ADAPs. The aim of this research is to assess the effectiveness of a new motivational strategy adapted to IPVAW offenders with ADAPs, aiming to increase treatment adherence and to improve BIPs outcomes. The motivational strategy will include an individualized motivational plan (IMP) developed for each participant with ADAPs (IMP-ADAPs). In these IMPs one of the main aims will be to reduce alcohol and/or drug consumption. The current study will use a randomized control trial. Participants with ADAPs will be allocated to one of two treatment conditions: experimental condition: Standard batterer intervention program (SBIP) plus individualized motivational plan focused in ADAPs (SBIP+ ADAPs-IMP), and control condition: Standard batterer intervention program plus individualized motivational plan (SBIP+IMP). Primary/final outcomes will be recidivism and ADAPs reduction. Secondary/proximal outcomes will include treatment adherence related variables, violence related attitudes and attributions, self-control and psychological adjustment. Outcome variables will be assessed at baseline, at the end of the intervention, and at six months after the intervention will be finished.


Eligibility Criteria:
Inclusion Criteria:

* Males convicted of IPV against their partner or ex-partner
* Alcohol and/or drugs abuse problems

Exclusion Criteria:

* No current severe psychological disorders
The Effect of High vs. Moderate Protein Consumption on Human Health

The study will be conducted as a parallel randomized controlled intervention trial, initiated by eight weeks rapid weight loss with one of two VLCDs, one week of reintroducing regular foods, and 12 weeks with one of two different ad libitum diets; in total 21 weeks. The study will be blinded for the statistician. Due to obvious different dietary intakes in the two diets, subjects cannot be blinded and neither the study personnel. As the study includes different dietary recommendations the registered clinical dietician advising the subjects cannot be blinded either.

In total 110 overweight and obese volunteers will be included.


Eligibility Criteria:
Inclusion Criteria:

* Healthy men or women
* Age, 18-65 years
* Overweight or grade I-II obesity (BMI 28-40.0 kg/m2)
* Provided voluntary written informed consent

Exclusion Criteria (main:

* Weight changes ± 5% in the last three months
* Vegetarian, vegan
* Pregnancy or lactation, pregnancy within the past 12 month or plans to become pregnant during the study
* History or diagnosis of diabetes
* History or diagnosis of heart, liver or kidney disease
* History or diagnosis of eating disorders
* Chronic diseases e.g. cancer within the past 5 years (except adequately-treated localized basal cell skin cancer)
* Simultaneous blood donation for other purpose than this study
* Simultaneous participation in other clinical intervention studies
* Use of drugs, that in the opinion of the medically responsible investigator, are likely to affect the outcomes of the study
* Any other condition that judged by the investigator may interfere with the adherence to the study protocol
Effect of Premedication With Pronase on Mucosal Cleanliness During EGD

Gastric cancer and esophageal cancer are common malignant tumors that threaten people's life and health. Esophagogastroduodenoscopy (EGD) is an important tool for screening upper gastrointestinal tumors, especially early tumors, and an effective method for detecting other upper gastrointestinal lesions, including ulcers and polyps. However, during EGD examination, mucus and foam can reduce the cleanliness of the mucosa and limit the operator's visual field, resulting in missed lesions and misdiagnosis. Previous studies have shown that preoperative medication with pronase and dimeticone is correlated with the improvement of upper gastrointestinal mucosal cleanliness. However, the number of samples in such studies is limited, and the artificial judgment is not objective enough to evaluate the cleanliness of upper digestive tract mucosa. And, whether a postural exercise is necessary for premedication with pronase or dimeticone remains unclear. Our team design this experiment to examine the efficacy of using premedication of dimeticone/pronase with a postural exercise on visualization of the mucosa before painless EGD. The investigators aim to provide new evidence to optimize the use of premedication with EGD.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female aged ≥18 years and ≤70 years;
2. Voluntarily participate in the trial and sign the informed consent.

Exclusion Criteria:

1. active gastrointestinal bleeding;
2. esophageal stricture, complete pyloric obstruction and gastroparesis caused by various reasons;
3. diagnosed malignant tumors of the upper digestive tract;
4. a history of upper gastrointestinal surgery;
5. severe heart, liver and kidney diseases, and the doctor judges that it is not suitable for painless gastroscopy;
6. serious mental illness;
7. pregnancy or breastfeeding;
8. an allergy to pronase or dimeticone;
9. current participation in other clinical trials and in the follow-up or drug washout period;
10. patients considered by the investigator to be unsuitable for this study
Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer

After Axillary lymphadenectomy for breast cancer there are not few patients showed seroma formation and it can not be ignored.Investigators aimed to study two new methods of application of Microfibrillar Collagen Hemostat Flour and OK-432 to reduce seroma formation and to verify the efficacy and safety of these two applications.Try to prove them as beneficial supplements for axillary lymphadenectomy of breast cancer.

A prospective,randomized analysis of breast-conserving surgery or mastectomy plus axillary lymphadenectomy for those patients with sentinel node positive using Microfibrillar Collagen Hemostat Flour 、 OK-432 or using nothing in equal probability.Up to 12 months,a total of 180 will be recruited in plan.During the operation and after the axillary lymphadenectomy，according the arms，Investigators put Microfibrillar Collagen Hemostat Flour（avitene）、 OK-432（Sapylin） or nothing into patients axillary wounds。And Investigators will the statistical significance of these three arms that the postoperative drainage magnitude and duration.Also the complications associated with axillary lymphadenectomy will be studied.

Eligibility Criteria:
Inclusion Criteria:

1. Patients volunteered for the study and signed informed consent；
2. Preoperative biopsy or intraoperative sentinel lymph node biopsy confirmed axillary lymph node metastasis and need axillary lymphadenectomy
3. No penicillin allergy
4. No blood system diseases
5. No rheumatic heart disease
6. No history or family history of asthma
7. No history of axillary surgery

Exclusion Criteria:

1. A history of severe hypertension
2. A history of diabetes
3. Undergoing anticoagulant therapy or anticoagulant therapy drug withdrawal less than a year
4. BMI\>30
5. Can not accept telephone follow-up or can not go to the hospital for subsequent inspection treatment
MBI in Generation Z Nursing Students During Clinical Practicum

This study is a randomized clinical trial design. The research subjects were the internship nursing students in the nursing department of a nursing school in the northern Taiwan.

The experimental group received mindfulness-based stress reduction intervention, while the control group received routine care with weekly line care messages from class instructors. Both groups took the post-test before the internship (T0), during the internship (T1), after the internship (T2), and one month after the internship (T3), a total of 4 times. The contents include psychological well-being scale; anxiety, depression, stress scale and mental scale.

Students need to learn a lot of new medical knowledge and skills during clinical internships, which requires time and effort. However, this kind of learning pressure may put a considerable burden on nursing students, especially anxiety, depression, and stress. Through effective coping strategies, students can improve their confidence in facing clinical situations.

Mindfulness-based stress reduction is a stress-reduction method based on mindfulness meditation. It can relieve the physical and mental stress and anxiety of high-stress people, improve sleep quality, chronic fatigue, and enhance concentration.

The purpose of this study is to explore the effectiveness of mindfulness-based stress reduction intervention on anxiety, depression, and stress in clinical practice of nursing students.

This study adopted a randomized clinical experimental research design. Nursing students from a fifth-level college in the north were selected as the research subjects. A total of 80 people were recruited. Nursing intern students who were willing to participate in the study were randomly assigned and divided into an experimental group of 40 people and a control group. 40 people, the experimental group participated in the mindfulness-based stress reduction course for 8 weeks. The mindfulness-based stress reduction course was led by a certified mindfulness-based stress reduction teacher, once a week, 2 hours each time, for 8 consecutive weeks; the students in the control group received weekly line care messages from the class instructor. Research tools include the General Health Status Scale, Anxiety and Depression Stress Scale, and Mental Resilience Scale. The data were analyzed using SPSS20.0 for Windows.

Eligibility Criteria:
Inclusion Criteria:

* (1) Nursing students during clinical practicum (2) Clear consciousness.

Exclusion Criteria:

-(1) Students diagnosed with schizophrenia, anxiety, depression or affective psychosis.

(2)Taking anti-anxiety medicine treatment or anti-depressant medicine treatment.
A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects

The purpose of this clinical research study is to determine if different dosage regimens of Sinemet® CR (Carbidopa/levodopa) are dose proportional


Eligibility Criteria:
* Key inclusion and exclusion criteria for healthy volunteers will be used
* Males and females aged 50-75
Computational Drug Repurposing for All EBS Cases

The study will compare gene expression differences between blistered and non-blistered skin from individuals with all subtypes of EB, as well as normal skin from non-EB subjects. State of the art computational analysis will be performed to help identify new drugs that might help all EB wound healing and reduce pain. Researchers will focus on drugs that have already been approved for treatment of other dermatologic or non-dermatologic diseases, and therefore be repurposed for treatment of EB. Drug development is a very expensive process taking decades for execution. Drug repurposing on the other hand, significantly reduces the cost and shortens the amount of time that is needed to bring effective treatments to clinical use. To date, there is no specific treatment targeting the physiology and immunologic response in EB patients during wound healing. Market availability of repurposed medications will provide all EB patients rapid access to treatments, thus improving their quality of life.

Although gene, cell, and protein-based therapies are in development for patients suffering from all subtypes of epidermolysis bullosa (EB), new pharmacological treatments are in dire need. Characterizing molecular changes in EB, including gene expression, can identify new therapeutic targets and drugs that modulate those targets. However, sifting through gene expression information to identify the most promising drug targets is a complex data challenge. The goal of the study will identify a computational approach to evaluate and identify existing drugs approved for other diseases that can be repurposed for EB patients. The study will perform an unprecedented characterization of gene expression changes in EB patients compared to healthy, non-EB individuals across multiple tissues. Using a validated computational drug discovery platform, researchers will analyze gene expression and drug data using unique algorithms. In the first year, a list of ten, safety drugs more probable to treat the EB disease state will be identified. The most promising drugs discovered will then be tested in the clinic setting.

Eligibility Criteria:
Inclusion Criteria:

* Subjects of all ages
* Diagnosis of all subtypes of EB subjects
* Healthy, non-EB subjects
* Ability to complete study visit to collect tissue and blood specimen

Exclusion Criteria:

* Pregnancy, breast feeding
* Prior history of liver disease
* Serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent tissue collection from subjects
General Anesthesia Versus Loco-Regional Anesthesia for Transcarotid Trancatheter Aortic Valve Replacement

Transcarotid transcatheter aortic valve replacement (Transcarotid TAVR) has been increasingly used as an alternative to the transfemoral approach. The general anesthesia, locoragional anesthesia or local anesthesia are three anesthesia techniques that can be used for transcarotid TAVR. We aim to compare the locoregional approach to gerneral anesthesia.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients who underwent a transcarotid TAVR at the University Hospital of Caen between October 2021 (when the first TAVR was performed under locoregional anesthesia) and December 2024

Exclusion Criteria:

* Patient's refusal to allow data collection and lack of data regarding the primary endpoint
A Drug Drug Interaciton Study of Imrecoxib and Warfarin in Healthy Volunteers

The objective of this study was to determine the effects of Imrecoxib, an anti-infiammatory/analgesic agent that primarily inhibits COX-2 and not COX-1 at therapeutic doses, on the steady-state pharmacokinetic profile and hypoprothrombinemic effect of warfarin in healthy volunteers.

This is a single center open label study to assess the effect of Imrecoxib on the PK of Warfarin in Healthy Volunteers. The goals of this study are as follows: assess the PK of warfarin when administered alone ,and with Imrecoxib ; assess INR of warfarin when administered alone, and with Imrecoxib; to assess the effect of Imrecoxib on the PK/PD of warfarin, to assess the safety and tolerability of warfarin administered with Imrecoxib.

Eligibility Criteria:
Inclusion Criteria:

Adult males aged 18 to 40 years,with BMI 19\~24.

Subjects who, in the opinion of the investigator, are healthy as determined by medical history, physical examination, and 12 Lead ECG.

Willing and able to provide written informed consent.

Exclusion Criteria:

History of hypersensitivity to Imrecoxib and its components.

History or current clinically important systemic illnesses, including but not limited to cardiovascular, pulmonary, hepatobiliary, renal, hematological, gastrointestinal, endocrinological, immunological, dermatological, neurological, or psychiatric diseases, or any conditions that may place the subject at increased risk as determined by the investigator.

Any condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.

History of alcohol dependent, habitual heavy users of caffeinated beverages judged by the investigator.

Have had significant blood loss (\>200mL) or have donated 1 or more units of blood or plasma within 12 weeks prior to study entry.

Have a positive test at Screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (HCVAb).

Have used any drugs or substances (including herbal supplements) known to inhibit or induce cytochrome (CYP) P450enzymesincluding CYP3A4, CYP2C8 and CYP2C9 within 4 weeks prior to the first dose and throughout the study.
Use of Virtual Reality and Video Games in the Physiotherapy Treatment of Stroke Patients

Randomized clinical trial based on the application of virtual reality and video games together with physiotherapy treatment in stroke patients, with the main objective of determining their beneficial effects.

21 participants who will be divided by randomization between a control group and an experimental group. The results will be quantified with the following scales: Modified Asworth (spasticity). Daniels et al (muscle strength) Tinetti (balance and gait) Berg (balance) Joint range

Eligibility Criteria:
Inclusion Criteria:

* Patients receiving neurological physiotherapy treatment.
* Patients who have suffered a stroke in the last two years.
* Patients with an age range between 18 and 80 years old.
* Patients with stroke with the ability to have minimal manual pressure with one limb.

Exclusion Criteria:

* Patients with stroke who also have degenerative diseases such as Alzheimer's or Parkinson's.
* Stroke patients who do not understand the instructions.
* Patients who have undergone surgery on the evaluated limbs.
* Patients with scars that limit movement.